1 Market Overview

1.1 Granulomatosis with Polyangiitis Drug Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Granulomatosis with Polyangiitis Drug Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 Benralizumab

1.2.3 Avacopan

1.2.4 Rituximab Biosimilar

1.2.5 Others

1.3 Market Analysis by Application

1.3.1 Overview: Global Granulomatosis with Polyangiitis Drug Revenue by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Granulomatosis with Polyangiitis Drug Market Size & Forecast

1.4.1 Global Granulomatosis with Polyangiitis Drug Sales in Value (2017 & 2021 & 2028)

1.4.2 Global Granulomatosis with Polyangiitis Drug Sales in Volume (2017-2028)

1.4.3 Global Granulomatosis with Polyangiitis Drug Price (2017-2028)

1.5 Global Granulomatosis with Polyangiitis Drug Production Capacity Analysis

1.5.1 Global Granulomatosis with Polyangiitis Drug Total Production Capacity (2017-2028)

1.5.2 Global Granulomatosis with Polyangiitis Drug Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 Granulomatosis with Polyangiitis Drug Market Drivers

1.6.2 Granulomatosis with Polyangiitis Drug Market Restraints

1.6.3 Granulomatosis with Polyangiitis Drug Trends Analysis

2 Manufacturers Profiles

2.1 Bionovis SA

2.1.1 Bionovis SA Details

2.1.2 Bionovis SA Major Business

2.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Product and Services

2.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 Bristol-Myers Squibb Company

2.2.1 Bristol-Myers Squibb Company Details

2.2.2 Bristol-Myers Squibb Company Major Business

2.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Services

2.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 ChemoCentryx Inc

2.3.1 ChemoCentryx Inc Details

2.3.2 ChemoCentryx Inc Major Business

2.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Services

2.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Coherus BioSciences Inc

2.4.1 Coherus BioSciences Inc Details

2.4.2 Coherus BioSciences Inc Major Business

2.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Services

2.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 Genor BioPharma Co Ltd

2.5.1 Genor BioPharma Co Ltd Details

2.5.2 Genor BioPharma Co Ltd Major Business

2.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Services

2.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6 GlaxoSmithKline Plc

2.6.1 GlaxoSmithKline Plc Details

2.6.2 GlaxoSmithKline Plc Major Business

2.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Services

2.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7 Iltoo Pharma

2.7.1 Iltoo Pharma Details

2.7.2 Iltoo Pharma Major Business

2.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Services

2.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8 Panacea Biotec Ltd

2.8.1 Panacea Biotec Ltd Details

2.8.2 Panacea Biotec Ltd Major Business

2.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Services

2.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9 Sandoz International GmbH

2.9.1 Sandoz International GmbH Details

2.9.2 Sandoz International GmbH Major Business

2.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Services

2.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10 The International Biotechnology Center (IBC) Generium

2.10.1 The International Biotechnology Center (IBC) Generium Details

2.10.2 The International Biotechnology Center (IBC) Generium Major Business

2.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Services

2.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 Granulomatosis with Polyangiitis Drug Breakdown Data by Manufacturer

3.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Granulomatosis with Polyangiitis Drug

3.4 Market Concentration Rate

3.4.1 Top 3 Granulomatosis with Polyangiitis Drug Manufacturer Market Share in 2021

3.4.2 Top 6 Granulomatosis with Polyangiitis Drug Manufacturer Market Share in 2021

3.5 Global Granulomatosis with Polyangiitis Drug Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Granulomatosis with Polyangiitis Drug Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global Granulomatosis with Polyangiitis Drug Market Size by Region

4.1.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2017-2028)

4.1.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2028)

4.2 North America Granulomatosis with Polyangiitis Drug Revenue (2017-2028)

4.3 Europe Granulomatosis with Polyangiitis Drug Revenue (2017-2028)

4.4 Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue (2017-2028)

4.5 South America Granulomatosis with Polyangiitis Drug Revenue (2017-2028)

4.6 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue (2017-2028)

5 Market Segment by Type

5.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Type (2017-2028)

5.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2028)

5.3 Global Granulomatosis with Polyangiitis Drug Price by Type (2017-2028)

6 Market Segment by Application

6.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Application (2017-2028)

6.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2028)

6.3 Global Granulomatosis with Polyangiitis Drug Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)

7.2 North America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)

7.3 North America Granulomatosis with Polyangiitis Drug Market Size by Country

7.3.1 North America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028)

7.3.2 North America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)

8.2 Europe Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)

8.3 Europe Granulomatosis with Polyangiitis Drug Market Size by Country

8.3.1 Europe Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028)

8.3.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)

9.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)

9.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size by Region

9.3.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application

10.1 South America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)

10.2 South America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)

10.3 South America Granulomatosis with Polyangiitis Drug Market Size by Country

10.3.1 South America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028)

10.3.2 South America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application

11.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type (2017-2028)

11.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2017-2028)

11.3 Middle East & Africa Granulomatosis with Polyangiitis Drug Market Size by Country

11.3.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of Granulomatosis with Polyangiitis Drug and Key Manufacturers

12.2 Manufacturing Costs Percentage of Granulomatosis with Polyangiitis Drug

12.3 Granulomatosis with Polyangiitis Drug Production Process

12.4 Granulomatosis with Polyangiitis Drug Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Granulomatosis with Polyangiitis Drug Typical Distributors

13.3 Granulomatosis with Polyangiitis Drug Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global Granulomatosis with Polyangiitis Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global Granulomatosis with Polyangiitis Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. Bionovis SA Basic Information, Manufacturing Base and Competitors

Table 4. Bionovis SA Major Business

Table 5. Bionovis SA Granulomatosis with Polyangiitis Drug Product and Services

Table 6. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors

Table 8. Bristol-Myers Squibb Company Major Business

Table 9. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Services

Table 10. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. ChemoCentryx Inc Basic Information, Manufacturing Base and Competitors

Table 12. ChemoCentryx Inc Major Business

Table 13. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Services

Table 14. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Coherus BioSciences Inc Basic Information, Manufacturing Base and Competitors

Table 16. Coherus BioSciences Inc Major Business

Table 17. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Services

Table 18. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. Genor BioPharma Co Ltd Basic Information, Manufacturing Base and Competitors

Table 20. Genor BioPharma Co Ltd Major Business

Table 21. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Services

Table 22. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors

Table 24. GlaxoSmithKline Plc Major Business

Table 25. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Services

Table 26. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 27. Iltoo Pharma Basic Information, Manufacturing Base and Competitors

Table 28. Iltoo Pharma Major Business

Table 29. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Services

Table 30. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 31. Panacea Biotec Ltd Basic Information, Manufacturing Base and Competitors

Table 32. Panacea Biotec Ltd Major Business

Table 33. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Services

Table 34. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 35. Sandoz International GmbH Basic Information, Manufacturing Base and Competitors

Table 36. Sandoz International GmbH Major Business

Table 37. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Services

Table 38. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 39. The International Biotechnology Center (IBC) Generium Basic Information, Manufacturing Base and Competitors

Table 40. The International Biotechnology Center (IBC) Generium Major Business

Table 41. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Services

Table 42. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 43. Global Granulomatosis with Polyangiitis Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)

Table 44. Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 45. Market Position of Manufacturers in Granulomatosis with Polyangiitis Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 46. Global Granulomatosis with Polyangiitis Drug Production Capacity by Company, (K Pcs): 2020 VS 2021

Table 47. Head Office and Granulomatosis with Polyangiitis Drug Production Site of Key Manufacturer

Table 48. Granulomatosis with Polyangiitis Drug New Entrant and Capacity Expansion Plans

Table 49. Granulomatosis with Polyangiitis Drug Mergers & Acquisitions in the Past Five Years

Table 50. Global Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022) & (K Pcs)

Table 51. Global Granulomatosis with Polyangiitis Drug Sales by Region (2023-2028) & (K Pcs)

Table 52. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022) & (USD Million)

Table 53. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2023-2028) & (USD Million)

Table 54. Global Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 55. Global Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)

Table 56. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2017-2022) & (USD Million)

Table 57. Global Granulomatosis with Polyangiitis Drug Revenue by Type (2023-2028) & (USD Million)

Table 58. Global Granulomatosis with Polyangiitis Drug Price by Type (2017-2022) & (USD/Pcs)

Table 59. Global Granulomatosis with Polyangiitis Drug Price by Type (2023-2028) & (USD/Pcs)

Table 60. Global Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 61. Global Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)

Table 62. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2017-2022) & (USD Million)

Table 63. Global Granulomatosis with Polyangiitis Drug Revenue by Application (2023-2028) & (USD Million)

Table 64. Global Granulomatosis with Polyangiitis Drug Price by Application (2017-2022) & (USD/Pcs)

Table 65. Global Granulomatosis with Polyangiitis Drug Price by Application (2023-2028) & (USD/Pcs)

Table 66. North America Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)

Table 67. North America Granulomatosis with Polyangiitis Drug Sales by Country (2023-2028) & (K Pcs)

Table 68. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & (USD Million)

Table 69. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2023-2028) & (USD Million)

Table 70. North America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 71. North America Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)

Table 72. North America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 73. North America Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)

Table 74. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)

Table 75. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2023-2028) & (K Pcs)

Table 76. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & (USD Million)

Table 77. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2023-2028) & (USD Million)

Table 78. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 79. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)

Table 80. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 81. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)

Table 82. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022) & (K Pcs)

Table 83. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2023-2028) & (K Pcs)

Table 84. Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022) & (USD Million)

Table 85. Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2023-2028) & (USD Million)

Table 86. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 87. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)

Table 88. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 89. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)

Table 90. South America Granulomatosis with Polyangiitis Drug Sales by Country (2017-2022) & (K Pcs)

Table 91. South America Granulomatosis with Polyangiitis Drug Sales by Country (2023-2028) & (K Pcs)

Table 92. South America Granulomatosis with Polyangiitis Drug Revenue by Country (2017-2022) & (USD Million)

Table 93. South America Granulomatosis with Polyangiitis Drug Revenue by Country (2023-2028) & (USD Million)

Table 94. South America Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 95. South America Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)

Table 96. South America Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 97. South America Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)

Table 98. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Region (2017-2022) & (K Pcs)

Table 99. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Region (2023-2028) & (K Pcs)

Table 100. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Region (2017-2022) & (USD Million)

Table 101. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Region (2023-2028) & (USD Million)

Table 102. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type (2017-2022) & (K Pcs)

Table 103. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Type (2023-2028) & (K Pcs)

Table 104. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2017-2022) & (K Pcs)

Table 105. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Application (2023-2028) & (K Pcs)

Table 106. Granulomatosis with Polyangiitis Drug Raw Material

Table 107. Key Manufacturers of Granulomatosis with Polyangiitis Drug Raw Materials

Table 108. Direct Channel Pros & Cons

Table 109. Indirect Channel Pros & Cons

Table 110. Granulomatosis with Polyangiitis Drug Typical Distributors

Table 111. Granulomatosis with Polyangiitis Drug Typical Customers

List of Figures

Figure 1. Granulomatosis with Polyangiitis Drug Picture

Figure 2. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type in 2021

Figure 3. Benralizumab

Figure 4. Avacopan

Figure 5. Rituximab Biosimilar

Figure 6. Others

Figure 7. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application in 2021

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Others

Figure 11. Global Granulomatosis with Polyangiitis Drug Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028

Figure 12. Global Granulomatosis with Polyangiitis Drug Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global Granulomatosis with Polyangiitis Drug Sales (2017-2028) & (K Pcs)

Figure 14. Global Granulomatosis with Polyangiitis Drug Price (2017-2028) & (USD/Pcs)

Figure 15. Global Granulomatosis with Polyangiitis Drug Production Capacity (2017-2028) & (K Pcs)

Figure 16. Global Granulomatosis with Polyangiitis Drug Production Capacity by Geographic Region: 2022 VS 2028

Figure 17. Granulomatosis with Polyangiitis Drug Market Drivers

Figure 18. Granulomatosis with Polyangiitis Drug Market Restraints

Figure 19. Granulomatosis with Polyangiitis Drug Market Trends

Figure 20. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturer in 2021

Figure 21. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Manufacturer in 2021

Figure 22. Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 23. Top 3 Granulomatosis with Polyangiitis Drug Manufacturer (Revenue) Market Share in 2021

Figure 24. Top 6 Granulomatosis with Polyangiitis Drug Manufacturer (Revenue) Market Share in 2021

Figure 25. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2028)

Figure 26. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2017-2028)

Figure 27. North America Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (USD Million)

Figure 28. Europe Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (USD Million)

Figure 29. Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (USD Million)

Figure 30. South America Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (USD Million)

Figure 31. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue (2017-2028) & (USD Million)

Figure 32. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)

Figure 33. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2017-2028)

Figure 34. Global Granulomatosis with Polyangiitis Drug Price by Type (2017-2028) & (USD/Pcs)

Figure 35. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)

Figure 36. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2017-2028)

Figure 37. Global Granulomatosis with Polyangiitis Drug Price by Application (2017-2028) & (USD/Pcs)

Figure 38. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)

Figure 39. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)

Figure 40. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2017-2028)

Figure 41. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2017-2028)

Figure 42. United States Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 43. Canada Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 44. Mexico Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)

Figure 46. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)

Figure 47. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2017-2028)

Figure 48. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2017-2028)

Figure 49. Germany Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. France Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. United Kingdom Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Russia Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Italy Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2028)

Figure 55. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)

Figure 56. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2028)

Figure 57. Asia-Pacific Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2017-2028)

Figure 58. China Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Japan Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Korea Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. India Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Southeast Asia Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Australia Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. South America Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)

Figure 65. South America Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)

Figure 66. South America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2017-2028)

Figure 67. South America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2017-2028)

Figure 68. Brazil Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Argentina Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2017-2028)

Figure 71. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2017-2028)

Figure 72. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2017-2028)

Figure 73. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2017-2028)

Figure 74. Turkey Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Egypt Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Saudi Arabia Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. South Africa Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Manufacturing Cost Structure Analysis of Granulomatosis with Polyangiitis Drug in 2021

Figure 79. Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug

Figure 80. Granulomatosis with Polyangiitis Drug Industrial Chain

Figure 81. Sales Channel: Direct Channel vs Indirect Channel

Figure 82. Methodology

Figure 83. Research Process and Data Source